Toward a solution for Shigella/ETEC diarrhoea

SHIGETECVAX is a collaborative project funded by the European Union’s Horizon 2020 research and innovation programme that brings together experts from Austria, Bangladesh, Germany, Sweden and the United States with proven track record in research and development with the aim of advancing a vaccine targeting the major causes of diarrhoeal diseases.  

TARGET DISEASE

Diarrhoeal Disease

TIMELINE

01 September 2019 – 31 October 2024

COORDINATOR

European Vaccine Initiative

Germany

FUNDER

European Union Horizon 2020

FUNDING

8.6M Euro

Diarrhoea is the most common disease globally. Although typically being a self-limiting condition in western civilisations, it can be a killer in low- and middle-income countries, where it is a leading cause of death and high morbidity for children under five years of age. 

 

Under the coordination of the European Vaccine Initiative (EVI), and partners including Eveliqure Biotechnologies (Austria), icddr, b (Bangladesh), University of Gothenburg (Sweden), and PATH (United States), the SHIGETECVAX consortium is dedicated to advancing a radically new approach developed by Eveliqure Biotechnologies. This combination vaccine is designed to prevent infections with Shigella and enterotoxigenic Escherichia coli (ETEC), two bacteria that cause significant cases of diarrhoea and suffering globally. 

No effective vaccines against these two pathogens exist, and this novel vaccine has the potential to provide cost-effective immunization option for populations in and travellers to endemic countries.    

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 815568

Join European Vaccine Initiative mailing list for updates on projects, training and funding opportunities

  • LinkedIn - White Circle
  • Twitter - White Circle

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 815568

Designed by European Vaccine Initiative